View Clinical Trial (Medical Research Study)
The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced "Brain Fog."
| City: |
|
New York |
| State: |
|
New York |
| Zip Code: |
|
10003 |
| Conditions: |
|
Fibromyalgia |
| Purpose: |
|
Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for
completing complex tasks relative to placebo.
|
| Study Summary: |
|
Fibromyalgia patients will show elevated ventricular lactate levels as measured via magnetic
resonance spectroscopy (MRS). Patients treated with Milnacipran will show normalization of
ventricular lactate levels compared to those treated with placebo, and will also show
normalization of the increased latency to respond to complex reaction time probes compared
to those treated with placebo.
|
| Criteria: |
|
Inclusion Criteria:
- Female or male subjects who fulfill the American College of Rheumatology's case
definition for Fibromyalgia.
- 18 through 60 years of age
Exclusion Criteria:
- Pregnant or trying to become pregnant
- Taking any other SNRI or already taking milnacipran
- Patients who do not indicate their pain levels as less than substantial despite
their best care
- History of any psychotic disorder or history of alcoholism or drug abuse within 10
years of intake as determined by psychiatric diagnostic interview
- Presence of current depression as determined by psychiatric diagnostic interview
- Presence of brain lesion on MRI anatomical study
|
| NCT ID: |
|
NCT01108731 |
| Primary Contact: |
|
Principal Investigator
Benjamin H Natelson, MD
Beth Israel Medical Center
Diana Vu
Phone: 212-844-6747
Email: dvu@chpnet.org
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
New York, New York 10003
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|